scholarly journals Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia

2015 ◽  
Vol 38 (5) ◽  
pp. 645-654 ◽  
Author(s):  
Masatomo Miura
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Myeloid Leukemia ◽  
Therapeutic Drug

scholarly journals Role of Therapeutic Drug Monitoring and Challenges in the Management of Infantile Chronic Myeloid Leukemia

2021 ◽  
Vol 18 (2) ◽  
Author(s):  
Sneha Tandon ◽  
Raviraj Deshpande ◽  
Gaurav Narula ◽  
Maya Prasad ◽  
Amey Paradkar ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Myeloid Leukemia ◽  
Therapeutic Drug

Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory

2012 ◽  
Vol 27 (6) ◽  
pp. 690-697 ◽  
Author(s):  
Stéphane Bouchet ◽  
Karine Titier ◽  
Nicholas Moore ◽  
Régis Lassalle ◽  
Basmah Ambrosino ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Myeloid Leukemia ◽  
Therapeutic Drug

Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis

2019 ◽  
Vol 41 (12) ◽  
pp. 2558-2570.e7 ◽  
Author(s):  
Manuel García-Ferrer ◽  
Aneta Wojnicz ◽  
Gina Mejía ◽  
Dora Koller ◽  
Pablo Zubiaur ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Myeloid Leukemia ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Myeloid Leukemia ◽  
Meta Analysis ◽  
Therapeutic Drug

scholarly journals Successful determination of imatinib dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction.

2021 ◽  
Author(s):  
Ryosuke Nakahara ◽  
Takahiro Sumimoto ◽  
Ryota Tanaka ◽  
Masao Ogata ◽  
Hiroki Itoh
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Therapeutic Drug Monitoring ◽  
Renal Dysfunction ◽  
Drug Monitoring ◽  
Myeloid Leukemia ◽  
Therapeutic Drug ◽  
First Line ◽  
Acute Renal Dysfunction ◽  
First Line Treatment

Imatinib is used as first-line treatment for chronic myeloid leukemia (CML) even in patients with impaired renal function. We successfully used therapeutic drug monitoring to determine the dose for re-administration of imatinib in a CML patient who initiated dialysis for acute renal dysfunction associated with the initial imatinib therapy.

Sign in / Sign up

Export Citation Format

Share Document